of the Clinical Genetics Branch (CGB), and cosponsored by the NIH Office of Rare Diseases, the meeting focused on bringing clinicians and scientists studying DC together with affected patients and families in order to share recent findings, explore opportunities for future research, and empower patients with DC and their families to organize a support group.
DC is an inherited bone marrow failure and cancer predisposition syndrome characterized by exceedingly short germline telomeres. About half of the patients with this multisystem disorder have mutations in telomere biology genes (see figure 1). Patients with DC are being studied in NCI's Inherited Bone Marrow Failure Syndromes study (http://marrowfailure.cancer.gov). Recent advances in understanding the molecular pathogenesis of DC include the discovery of new causative genes and the development of a diagnostic test. These developments, coupled with the need for a DC-specific family support group expressed by families participating in the NCI study, prompted this workshop. The workshop resulted in the formation of collaborative studies involving the clinical, scientific, and patient communities. The research strategies will be key in advancing scientific understanding of the molecular pathogenesis of DC and telomere biology, as well as improving therapeutic options for patients with DC. A future meeting will focus on developing consensus treatment guidelines.
-June A. Peters, M.S., C.G.C.
